Romain Euvrard

Romain Euvrard

Auto-generated profile, based on publicly available information

Romain Euvrard

Service de médecine interne, centre hospitalier Alpes Léman, 558, route de Findrol, 74130, Contamine-sur-Arve, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2016 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ELEmeric Limagne
Emeric Limagne
RERomain Euvrard
Romain Euvrard
MTMarion Thibaudin
Marion Thibaudin
CRCédric REBE
Cédric REBE
VDValentin Derangère
Valentin Derangère
Ghiringhelli FrançoisGhiringhelli François
Ghiringhelli François
Host immunity controls the development of colorectal cancer, and chemotherapy used to treat colorectal cancer is likely to recruit the host immune system at some level. Athough preclinical studies have argued that colorectal cancer drugs, such as 5-fluorouracil (5-FU) and oxaliplatin, exert such effects, their combination as employed in the oncology clinic has not been evaluated. Here, we report the results of prospective immunomonitoring of 25 metastatic colorectal cancer (mCRC) patients treated with a first-line combination regimen of 5-FU, oxaliplatin, and bevacizumab (FOLFOX–bevacizumab), as compared with 20 healthy volunteers. Before this therapy was initiated, T regulatory cells (Treg), Th17, and granulocytic myeloid-derived suppressor cells (gMDSC) were increased significantly in mCRC, but only a high level of gMDSC was associated with a poor prognosis. Chemotherapy modulated the Treg/Th17 balance by decreasing Treg and increasing Th17 cell frequency by 15 days after the start of treatment. Increased Th17 frequency was associated with a poor prognosis. FOLFOX–bevacizumab treatment elicited a decrease in gMDSC in 15 of 25 patients and was associated with a better survival outcome. Notably, the gMDSCs that expressed high levels of PD-L1, CD39, and CD73 exerted a robust immunosuppressive activity, relative to other myeloid cells present in blood, which could be reversed by blocking the CD39/CD73 and PD-1/PD-L1 axes. Our work underscores the critical prognostic impact of early modifications in Th17 and gMDSC frequency in mCRC. Furthermore, it provides a clinical rationale to combine FOLFOX–bevacizumab chemotherapy with inhibitors of ATP ectonucleotidases and/or anti-PD-1/PD-L1 antibodies to more effectively treat this disease. Cancer Res; 76(18); 5241–52. ©2016 AACR.

1 April 2017 in Cell Reports
Verified
Journal Article
Open access
ELEmeric Limagne
Emeric Limagne
MTMarion Thibaudin
Marion Thibaudin
RERomain Euvrard
Romain Euvrard
HBHélène Berger
Hélène Berger
PCPauline Chalons
Pauline Chalons
Ghiringhelli FrançoisGhiringhelli François
Ghiringhelli François
Sirtuin-1 deacetylates proteins and has emerged as a critical regulator of different cellular processes, particularly inflammation. Basal SIRT1 activity was previously found to limit Th9 and enhance Th17 differentiation in mice, but the effect of pharmacological SIRT1 activation on T cell differentiation and antitumor responses remains unclear. Here, we find that SIRT1 pharmacological agonists selectively impede mouse and human Th17 cell differentiation. SIRT1 activation induces STAT3 deacetylation, thus reducing its ability to translocate into the nucleus, bind to Rorc promoter, and induce its transcription. SIRT1 agonists reduce tumor growth in mice by blocking Th17 cell differentiation. In cancer patients, the SIRT1 agonist metformin reduced the frequency of Th17 cells and STAT3 acetylation levels. Altogether, these data underscore that SIRT1 activation impedes Th17 cell differentiation and thereby limits tumor growth and suggest that SIRT1 activators may directly target IL-17A functions.

7 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HBHélène Bugaut
Hélène Bugaut
Mélanie BruchardMélanie Bruchard
Mélanie Bruchard
HBHélène Berger
Hélène Berger
VDValentin Derangère
Valentin Derangère
LOLudivine Odoul
Ludivine Odoul
GMGrégoire Mignot
Grégoire Mignot
Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8+ T cells and interferon-γ. We also find that, in addition to its capacity to trigger immunogenic cell death, BLM induces expansion of Foxp3+ regulatory T (Treg) cells via its capacity to induce transforming growth factor beta (TGFβ) secretion by tumor cells. Accordingly, Treg cells or TGFβ depletion dramatically potentiates the antitumor effect of BLM. We conclude that BLM induces both anti-tumor CD8+ T cell response and a counteracting Treg proliferation. In the future, TGFβ or Treg inhibition during BLM treatment could greatly enhance BLM anti-tumor efficacy.

27 November 2023 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Open access
RERomain Euvrard
Romain Euvrard
MRMarie Robert
Marie Robert
SMSabine Mainbourg
Sabine Mainbourg
SDStéphane Dalle
Stéphane Dalle
JLJean‐Christophe Lega
Jean‐Christophe Lega
Background: Immune checkpoint inhibitors (ICI) represent a breakthrough in oncology in terms of prognosis and safety. They now constitute a cornerstone in the management of metastatic melanoma. However, a new kind of adverse event called immune‐related adverse events (irAE) has emerged. These irAE could be conceptually considered as an indicator of the antitumoral immune response, but the association between irAE and prognosis is still a matter of debate.Objective: The purpose of this study was to investigate the association between the overall survival (OS) and the prevalence of irAE in melanoma.Methods: MEDLINE/PubMed, WebofScience, ClinicalTrials, and WHOTrials databases were searched to identify phase 3 randomized controlled trials (RCT) assessing ICI in melanoma and published up to April 2021. A weighted regression was performed to estimate this association according to standard method of surrogacy analysis.Results: A total of 14 RCT including 7646 patients (median age: 59.3 years) with melanoma were included. All types of ICI were represented (ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, as well as ipilimumab and nivolumab combination). irAE were frequent but rarely fatal. The combination of ICI caused more irAE than anti‐PD1 (or PDL1) and anti‐CTLA4 monotherapies. No relationship was found between the occurrence of irAE and OS (beta coefficient 0.078, R2 3%, p = 0.52), nor between cutaneous irAE and OS (beta coefficient 0.080, R2 6%, p = 0.33).Conclusion: Although limited by the heterogeneity of ICI included in the regression and the low number of included RCT, the present study suggests an absence of association between irAE and prognosis in melanoma.

18 October 2024 in La Revue de Médecine Interne
Verified
Journal Article
Open access
FMFlorentin Masoch
Florentin Masoch
YRYoann Roubertou
Yoann Roubertou
CTClaire Triffault-Fillit
Claire Triffault-Fillit
SGSibylle Guillou
Sibylle Guillou
MMMarie Meignien
Marie Meignien
RERomain Euvrard
Romain Euvrard
Fever is a cosmopolit zoonosis due to Coxiella burnetii. The diagnosis of chronic Q fever can be really misleading. The growth of this bacterium is difficult and blood cultures are often negatives. We rapport here the case of a 69-year-old man presenting with an alteration of his general condition and low back pain. He suffered from a well-controlled HIV infection and lower limb arteriopathy treated with a cross-femoral bypass. A computed tomography scan revealed a L3-L4 abscessed spondylodiscitis but multiple blood cultures remained sterile, and the transthoracic echocardiography was normal. PET scan showed a hypermetabolism on L3-L4 vertebrae but also indicated an intense uptake of the cross-femoral bypass. C. burnetii serology was in favour of a chronic Q fever. The management of this chronic Q fever needed a multidisciplinary discussion. Three months after the treatment initiation, C. burnetii serology was reduced by a titer and has stabilized 6months to a year. Chronic Q fever and mostly osteoarticular diseases are difficult to diagnose. We have to evoke the diagnosis of osteoarticular chronic Q fever in case of insidious inflammatory syndrome, negatives blood cultures spondylodiscitis especially when associated to endocarditis or vascular infection, and in case of spondylodiscitis with a granulomatous histology without Mycobacterium tuberculosis. Although there are many complementary tests (PET scanner, PCR), serology remains the cornerstone of diagnosis.

14 March 2024 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
YRYoann Roubertou
Yoann Roubertou
RERomain Euvrard
Romain Euvrard
A 62-year-old man was referred to the hospital for recurrent pancreatitis. He had a medical history of hypertension, diabetes treated with insulin, and excessive alcohol consumption. A computed tomography (CT) scan was performed, showing mediastinal, hilar, and retroperitoneal lymphadenopathy. Pancreatic magnetic resonance imaging found features of autoimmune pancreatitis and a cirrhotic liver. A positron emission tomography (PET) scan found uptake in the thoracic lymph nodes (asterisk, Figure 1A), the anterior wall of the left ventricle, and a saccular aneurysm of 16 mm in diameter located on the infra-renal abdominal aorta (arrow, Figure 1A). The initial electrocardiogram showed sinus rhythm without ischaemic sign. A coronary angiography was performed, revealing a giant aneurysm, 20 mm in diameter, on the left anterior descending artery (arrow, Figure 1B). Laboratory tests revealed elevated IgG4 (8587 mg/L; normal value < 864 mg/L). Syphilis and intracellular bacteria serologies, including Coxiella and Bartonella, were negative. The blood culture was sterile. There was no clinical or biological evidence for other systemic vasculitis, such as antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, giant cell arteritis, or Behcet disease. An IgG4-related disease with pancreatic, lymphatic, aortic, and coronary involvement was diagnosed. The patient received corticosteroids with a total regression of the uptake on the PET scan performed at 2 months. The patient did not receive any endovascular or surgical treatment of the aneurysm because of the major bleeding risk linked to cirrhosis and thrombocytopenia.